AMS -2021-IMrh-Internal Medicine- Rheumatology(Downloadable)

$119.00

5 AMA PRA Category 1 Credits™
StreamingINCLUDED

Topics and Objectives

Title: IMrh-Internal Medicine- Rheumatology- Osteoporosis; Scleroderma and Raynaud’s Disease; Rheumatoid Arthritis.

Faculty: Linda Brecher D.O., F.A.C.O.I., F.A.C.R., Lawrence Brent M.D.

Original Release Date: July 1, 2021  Expiration Date: July 1, 2024

TOPIC 1: Osteoporosis.

Upon completion of this session, the participant should be able to: GL, EBM, COMP

  1. Detect patients who are at risk for osteoporosis.
  2. Recognize the need for bone density testing as recommended by the International Society of Clinical Densitomethy and the National Osteoporosis Foundation guidelines.
  3. Differentiate the nonpharmacologic and pharmacologic treatments for osteoporosis as recommended by the National Osteoporosis Foundation guidelines.

TOPIC 2: Scleroderma and Raynaud’s Disease.

Upon completion of this session, the participant should be able to: GL, COMP

  1. Specify the clinical manifestations of scleroderma.
  2. Apply the ACR/EULAR classification criteria for systemic sclerosis.
  3. Utilize treatment available for symptomatic manifestations as per the current EULAR recommendations.
  4. Apply the diagnostic work-up and treatment of Raynaud’s Phenomenon.

TOPIC 3: Rheumatoid Arthritis.

Upon completion of this session, the participant should be able to: GL, COMP

  1. Demonstrate the role of genetics, environmental factors, immune cells, and proinflammatory cytokines in the pathogenesis of rheumatoid arthritis.
  2. Illustrate the clinical features, extra-articular manifestations, and complications of rheumatoid arthritis.
  3. Utilize and compare various methods of measuring disease activity in rheumatoid arthritis.
  4. Compare and contrast the mechanisms of action of current and emerging therapies for RA and prescribe treatment for patients with rheumatoid arthritis according to ACR guidelines.


Total Cost: $

Title: IMrh-Internal Medicine- Rheumatology- Osteoporosis; Scleroderma and Raynaud’s Disease; Rheumatoid Arthritis.

Faculty: Linda Brecher D.O., F.A.C.O.I., F.A.C.R., Lawrence Brent M.D.

Original Release Date: July 1, 2021  Expiration Date: July 1, 2024

TOPIC 1: Osteoporosis.

Upon completion of this session, the participant should be able to: GL, EBM, COMP

  1. Detect patients who are at risk for osteoporosis.
  2. Recognize the need for bone density testing as recommended by the International Society of Clinical Densitomethy and the National Osteoporosis Foundation guidelines.
  3. Differentiate the nonpharmacologic and pharmacologic treatments for osteoporosis as recommended by the National Osteoporosis Foundation guidelines.

TOPIC 2: Scleroderma and Raynaud’s Disease.

Upon completion of this session, the participant should be able to: GL, COMP

  1. Specify the clinical manifestations of scleroderma.
  2. Apply the ACR/EULAR classification criteria for systemic sclerosis.
  3. Utilize treatment available for symptomatic manifestations as per the current EULAR recommendations.
  4. Apply the diagnostic work-up and treatment of Raynaud’s Phenomenon.

TOPIC 3: Rheumatoid Arthritis.

Upon completion of this session, the participant should be able to: GL, COMP

  1. Demonstrate the role of genetics, environmental factors, immune cells, and proinflammatory cytokines in the pathogenesis of rheumatoid arthritis.
  2. Illustrate the clinical features, extra-articular manifestations, and complications of rheumatoid arthritis.
  3. Utilize and compare various methods of measuring disease activity in rheumatoid arthritis.
  4. Compare and contrast the mechanisms of action of current and emerging therapies for RA and prescribe treatment for patients with rheumatoid arthritis according to ACR guidelines.